ADCTADC Therapeutics SA
This is the year ADC Therapeutics has to prove it’s not just another biotech with a fancy name and a lot of debt. The next catalyst — the announcement of participation in a strategic partnership or collaboration on 2026-09-11 — is the first real test. If the stock holds above $1.36 and climbs toward $1.55, it’s a sign the company is starting to move the needle. If it falls below $1.25, the bear path kicks in, and the whole narrative shifts. Either way, this is the moment the market will start to take ADC Therapeutics seriously — or not.
The Read
4% in Q2 2026 due to weak ZYNLONTA traction and cash concerns, then rallied 4%.
The schedule
No upcoming catalysts on the current packet.
Past
- Thu10Sep
Actual outcome: Bull · $1.28 at outcome
ADC Therapeutics announced progress in blood cancer treatment trials, signaling positive developments in their therapeutic pipeline. The stock rallied 15.8% following the news, reflecting investor confidence in the company's advancements and potential for future growth despite missing earnings expectations.
Announcement on progress in blood cancer treatment trials
- Thu6Aug
Actual outcome: Bear · $3.17 at outcome
ADCT reported in-line EPS of -$0.50, but the stock ultimately broke well below the $3.80 bear floor. The lack of convincing ZYNLONTA revenue acceleration and ambiguous messaging surrounding the LOTIS-5 regulatory update failed to provide the necessary fundamental support, driving the bearish outcome.
- Tue10Mar
Actual outcome: Bear · $3.80 at outcome
ADC Therapeutics reported a Q4 loss of $0.04 per share, beating consensus estimates, and delivered $22.3 million in quarterly net product revenue. Despite the financial beat and an amendment to their HealthCare Royalty financing agreement, the stock fell 20.8% by the outcome date, as the market lacked immediate near-term catalysts with LOTIS-5 Phase 3 topline data not expected until the second quarter of 2026.
